CANbridge Pharmaceuticals Inc. - Laporan Laba Rugi (TTM)

CANbridge Pharmaceuticals Inc.
HK ˙ SEHK ˙ KYG1821D1097
HK$ 2.45 ↑0.24 (10.86%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi CANbridge Pharmaceuticals Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 12 18 22 27 31 42 54 66 79 83 87 95 103 104 105 95 85 74 63
Change (%) 48.31 24.85 19.93 16.62 34.69 27.94 23.53 19.05 5.27 5.01 8.92 8.19 0.85 0.84 -9.33 -10.28 -13.25 -15.27
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 5 9 9 11 12 16 20 25 30 32 34 36 39 38 38 34 31 27 22
Change (%) 72.20 6.52 15.50 13.42 27.37 24.21 26.76 21.11 6.34 5.96 7.11 6.63 -1.31 -1.33 -9.14 -10.06 -13.85 -16.07
% of Revenue 42.84 49.73 42.43 40.87 39.75 37.59 36.49 37.44 38.09 38.47 38.82 38.18 37.63 36.82 36.03 36.10 36.19 35.94 35.60
Gross Operating Profit 7 9 13 16 19 26 34 41 49 51 53 59 64 66 67 61 54 47 40
Change (%) 30.42 42.99 23.20 18.83 39.52 30.19 21.68 17.82 4.61 4.41 10.07 9.15 2.15 2.11 -9.43 -10.41 -12.91 -14.82
% of Revenue 57.16 50.27 57.57 59.13 60.25 62.41 63.51 62.56 61.91 61.53 61.18 61.82 62.37 63.18 63.97 63.90 63.81 64.06 64.40
SG&A 129 149 181 213 246 255 247 221 196 190 184 179 174 168 162 153 143 125 107
Change (%) 15.46 21.57 18.15 15.36 3.39 -3.06 -10.36 -11.55 -3.00 -3.09 -2.84 -2.93 -3.19 -3.30 -5.96 -6.34 -12.63 -14.46
% of Revenue 1,069.85 832.89 810.96 798.91 790.30 606.67 459.65 333.54 247.80 228.34 210.73 187.97 168.66 161.90 155.26 161.02 168.10 169.29 170.91
R&D 110 168 349 388 428 440 311 311 311 304 296 277 257 272 287 270 252 174 96
Change (%) 53.43 107.21 11.34 10.19 2.84 -29.27 0.01 0.01 -2.46 -2.52 -6.54 -6.99 5.89 5.56 -6.21 -6.63 -30.84 -44.58
% of Revenue 911.25 942.72 1,564.61 1,452.54 1,372.41 1,047.86 579.33 469.03 394.03 365.11 338.95 290.85 250.03 262.53 274.81 284.24 295.83 235.85 154.25
OpEx 244 326 539 613 686 710 577 557 537 525 514 492 469 479 488 457 426 326 226
Change (%) 33.76 65.39 13.70 12.05 3.48 -18.68 -3.51 -3.64 -2.16 -2.21 -4.31 -4.51 1.94 1.90 -6.36 -6.79 -23.49 -30.70
% of Revenue 2,023.94 1,825.35 2,418.00 2,292.32 2,202.46 1,692.12 1,075.47 840.01 679.91 631.92 588.51 517.00 456.32 461.25 466.10 481.36 500.12 441.08 360.76
Operating Income -231 -308 -516 -586 -655 -668 -524 -491 -458 -442 -426 -396 -367 -375 -383 -362 -341 -252 -163
Change (%) 33.00 67.74 13.43 11.84 1.99 -21.61 -6.28 -6.71 -3.44 -3.56 -7.02 -7.55 2.24 2.19 -5.54 -5.87 -26.05 -35.22
% of Revenue -1,923.94 -1,725.35 -2,318.00 -2,192.32 -2,102.46 -1,592.12 -975.47 -740.01 -579.91 -531.92 -488.51 -417.00 -356.32 -361.25 -366.10 -381.36 -400.12 -341.08 -260.76
Interest Expense -4 -3 -3 -3 -3 -3 -4 -5 -7 -8 -9 -9 -9 -9 -9 -9 -9 -7 -6
Change (%) -13.44 -0.37 -2.95 -3.04 12.89 15.16 35.72 26.32 14.40 12.59 0.61 0.61 0.61 0.61 -2.62 -2.69 -16.31 -19.49
% of Revenue -31.53 -18.40 -14.69 -11.88 -9.88 -8.28 -7.45 -8.19 -8.69 -9.44 -10.13 -9.35 -8.70 -8.68 -8.66 -9.30 -10.09 -9.73 -9.25
Net Income -846 -828 -1,034 -1,055 -1,077 -1,089 -982 -733 -483 -468 -453 -416 -379 -393 -408 -425 -443 -289 -136
Change (%) -2.15 24.84 2.10 2.06 1.13 -9.85 -25.38 -34.01 -3.19 -3.30 -8.15 -8.87 3.84 3.70 4.25 4.08 -34.62 -52.96
% of Revenue -7,031.61 -4,639.27 -4,638.76 -3,949.26 -3,456.26 -2,595.07 -1,828.44 -1,104.47 -612.21 -563.01 -518.50 -437.23 -368.26 -379.20 -389.95 -448.33 -520.10 -391.93 -217.58

Source: Capital IQ

Other Listings
DE:MF1 € 0.20
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista